유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, kronični - antivirusi za sistemsko uporabo - victrelis je indicirano za zdravljenje kroničnega hepatitisa c (chc) genotip 1 okužbe, v kombinaciji z peginterferon alfa in ribavirin pri odraslih bolnikih z nadomestiti bolezen jeter, ki so predhodno nezdravljenih ali ki niso prejšnje zdravljenje.

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, kronični - antivirusi za sistemsko uporabo - incivo, v kombinaciji z peginterferon alfa in ribavirin, je primerna za zdravljenje genotip-1 kronični hepatitis c pri odraslih bolnikih z odškodnina za bolezni jeter (vključno s cirozo):kdo so zdravljenje naivna;, ki so že bili zdravljeni z interferonom alfa (pegylated ali ne-pegylated) sam ali v kombinaciji z ribavirin, vključno z relapsers, delno odzvali in nič na kraju nesreče.

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitis c, kronični - antivirusi za sistemsko uporabo - zdravilo olysio je indicirano v kombinaciji z drugimi zdravili za zdravljenje kroničnega hepatitisa c (chc) pri odraslih bolnikih. za virus hepatitisa c (hcv) genotip določene dejavnosti,.

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

roche d.o.o. - ribavirin - filmsko obložena tableta - ribavirin 200 mg / 1 tableta - ribavirin

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daklatasvir dihidroklorid - hepatitis c, kronični - antivirusi za sistemsko uporabo - zdravilo daklinza je indicirano v kombinaciji z drugimi zdravili za zdravljenje okužbe s kroničnim hepatitisom c (hcv) pri odraslih (glejte poglavja 4. 2, 4. 4 in 5. za hcv genotip določene dejavnosti, glej točki 4. 4 in 5.

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbvie d.o.o. - ribavirin - filmsko obložena tableta - ribavirin 400 mg / 1 tableta - ribavirin

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbvie d.o.o. - ribavirin - filmsko obložena tableta - ribavirin 600 mg / 1 tableta - ribavirin

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbvie d.o.o. - ribavirin - filmsko obložena tableta - ribavirin 200 mg / 1 tableta - ribavirin

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir - hepatitis c, kronični - antivirusi za sistemsko uporabo - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip določene dejavnosti, glej točki 4. 4 in 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip določene dejavnosti, glej točki 4. 4 in 5.

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.